Oral Disodium Cromoglycate Treatment of A topic Dermatitis

Publisher Website
Google Scholar
Abstract
Adults (14) and children (10) with active atopic dermatitis entered this double blind cross-over study of oral disodium cromoglycate (DSCG) (adults 200 mg qid [4 times/day], children 100 mg qid) compared with placebo. Oral DSCG and placebo were given for 6 wk in random order. According to the investigators'' assessments of eczema, significant differences between active and placebo were found after 6 wk treatment, DSCG being favored (P < 0.05). No differences were detected in the investigators'' assessment of lichenization and overall disease. No significant differences between the 2 treatments were demonstrated in the patients'' assessments. Results from food allergic patients were similar to those from non-food allergic patients. Two patients reported possible side effects of arthralgia and urticaria, respectively. There were no treatment effects on serum IgE values or any other laboratory data.

This publication has 6 references indexed in Scilit: